Completed NA INTERVENTIONAL 6-arm NCT02355210

Use of a Novel Synbiotic to Change Human Gut Bacteria and Improve Health in Obese Adults

Application of a Novel Synbiotic to Modulate the Human Gut Microbiota and Improve Health

Sponsor: Rush University Medical Center

Conditions Intestinal Microbiota and Barrier Function

Interventions Bifidobacteria adolescentis BD1 Bifidobacteria adolescentis BD1 and galactooligosaccharide Bifidobacteria animalis subsp. lactis BB-12 Bifidobacteria animalis subsp. lactis BB-12 and galactooligosaccharide Placebo galactooligosaccharide

Updated 8 times since 2017 Last updated: Nov 19, 2021 Started: Jun 30, 2013 Primary completion: Aug 31, 2015 Completion: Oct 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Intestinal Microbiota and Barrier Function and is currently completed. Rush University Medical Center leads this study, which shows 8 recorded versions since 2013 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2023 — Jul 2024 [monthly]

Completed NA
Dec 2022 — Jan 2023 [monthly]

Completed NA
Dec 2021 — Dec 2022 [monthly]

Completed NA

▶ Show 3 earlier versions

Jan 2021 — Dec 2021 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Jun 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Rush University Medical Center
University of Alberta
University of Nebraska Lincoln

Data source: Rush University Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chicago, United States